Coroner Links CJC-1295 and Ipamorelin to Actor's Death

What the Victorian coroner found

Victorian Coroner David Ryan handed down his findings on Wednesday, October 28, 2026, on the death of Richard Norton, 75, a film fight choreographer and martial artist. He found Norton suffered a cardiac arrest in March 2025 after injecting CJC-1295 and ipamorelin, two unapproved products a doctor had prescribed to him¹²³.

The timeline published by the wire services runs like this¹³: in March 2025 Norton approached Dr Jerzy Muchnicki about peptide therapy; another practitioner had already prescribed him peptides for fatigue, shoulder pain and muscle loss. Before prescribing there were baseline blood tests and an informed-consent form listing risks including anaphylaxis, and they discussed the "experimental nature of the treatment" and the lack of TGA-approved alternatives. CJC-1295 and ipamorelin were prescribed on March 19. About a week later Norton said he was feeling good and his symptoms were improving. On March 28 he told a nurse he had been injecting double the prescribed amount; she advised him to return to the prescribed dose the following week, and the doctor prescribed two more peptides. Hours after an injection Norton felt hot and flushed and became unresponsive. He died at the Alfred Hospital on March 30, 2025¹³.

The recommendations to the TGA

Ryan recommended that Australia's Therapeutic Goods Administration (TGA) review the therapeutic benefits and safety risks of the peptides, and that the review consider moving them from Schedule 4 (prescription-only) to Schedule 10, which would restrict them to clinical trials or other experimental use¹²³. In his words, "I am not satisfied that it is appropriate for them to be available to be prescribed by medical practitioners," and "it is not clear to me how their safe use can be clinically indicated"¹³.

The TGA had already warned consumers about importing and using unapproved peptides; according to The Medical Republic, the unapproved peptides include BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295 as examples, and a "research use only" label does not make supply lawful⁴. According to The Medical Republic, Dr James Kelly, RACGP deputy faculty chair for NSW/ACT, said in April: "We have no evidence to suggest or support that any of these compounds do anything"⁴.

What the Medical Board said about the doctor

The Medical Board of Australia investigated Muchnicki. Its independent expert found "insufficient evidence that CJC1295 or Ipamorelin is safe, effective or beneficial for human use" and described his notes as "sparse, inadequate and perfunctory" and "substantially below the standard reasonably expected"¹². The doctor accepted the criticism, expressed sorrow to the family and committed not to prescribe peptides without robust clinical evidence. The Board decided regulatory action was not warranted but required one-on-one training in clinical record keeping and management¹².

What the literature shows about these two molecules

The scientific base for these molecules is hormone-secretion pharmacology. A randomized trial in healthy adults described prolonged stimulation of growth hormone and insulin-like growth factor I (IGF-I) secretion with CJC-1295, a long-acting analog of growth-hormone-releasing hormone⁵. Ipamorelin was described in 1998 as the first selective growth hormone secretagogue⁶. Both titles concern hormone secretion, not cardiovascular outcomes; what concerned the coroner was uncertain benefit and unknown risk¹³. A single death does not establish how frequent the risk is, and the news reports do not detail the mechanism.

Why it matters in the United States

On October 28, the same day as the Australian findings, HHS filed an enforcement-discretion policy covering six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500; it was published in the Federal Register on October 30⁷¹⁰¹¹. CJC-1295 and ipamorelin are not among them: legal coverage of the policy explicitly names CJC-1295, ipamorelin, AOD-9604 and emideltide as not covered⁸. Neither were they among the 12 peptides FDA removed from Category 2 in April¹³.

The contrast illustrates a question two countries' regulators answer in opposite ways: what to do with a market where these products are already prescribed and injected. Australia, through a coroner, asks whether they should remain prescribable¹³. The United States, through HHS, opens a regulated pathway with conditions for six of them, even though FDA's own scientists opposed it and an emergency physician warned that "most patients will take it as an FDA endorsement, even though HHS has said it isn't one"⁷⁹¹².

What to watch

• TGA: whether it agrees to review the peptides' scheduling or answers the coroner with another measure¹³.
• United States: public comments on the HHS policy close two weeks after October 30, and FDA expects another advisory committee consultation before February 2027⁷¹⁰¹³.
• Adverse events: HHS requires MedWatch reporting for the six covered peptides; FDA's system has logged 10 serious BPC-157 reports since 2021, 8 of them in 2026, which does not prove causation¹⁰¹².